Methods for modulating inflammatory and/or immune responses

• US 8,647,617 B2
• Filed: 05/30/2012
• Issued: 02/11/2014
• Est. Priority Date: 07/13/2009
• Status: Active Grant

• Current Assignee: Stemnion, Inc.
• Original Assignee: Stemnion, Inc.
• Inventors: Marshall, Vivienne S., Banas, Richard A., Trumpower, Catherine J.
• Primary Examiner(s): Marvich, Maria
• Application Number:
  US13/483,346
• Publication Number:
  US 20120264106A1
• Time in Patent Office: 622 Days
• Field of Search: None
• US Class Current: 424/93.21
• CPC Class Codes: A61K 2039/5158 Antigen-pulsed cells, e.g. T-cells
• CPC Class Codes: A61K 35/12 Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells vaccines or medicinal preparations containing antigens or antibodies A61K39/00
• CPC Class Codes: A61K 35/50 Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
• CPC Class Codes: A61K 38/1709 from mammals
• CPC Class Codes: A61K 38/19 Cytokines; Lymphokines; Interferons
• CPC Class Codes: A61K 38/21 Interferons [IFN]
• CPC Class Codes: A61K 39/001 Preparations to induce tolerance to non-self, e.g. prior to transplantation
• CPC Class Codes: A61K 39/3955 against proteinaceous materials, e.g. enzymes, hormones, lymphokines
• CPC Class Codes: A61K 39/461 characterised by the cell type used
• CPC Class Codes: A61K 39/464838 Viral antigens
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 9/08 Solutions composition of solutions A61K47/00
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: C12N 2502/025 extra-embryonic cells, e.g. amniotic epithelium, placental cells, Wharton's jelly
• CPC Class Codes: C12N 5/0634 Cells from the blood or the immune system

Abstract

The invention is directed to novel methods for modulating inflammatory and/or immune responses. Such methods utilize compositions comprising extraembryonic cells (herein referred to as EE cells) including but not limited to extraembryonic HLA-G positive cells (herein referred to as EHP cells) and amnion-derived multipotent progenitor cells (herein referred to as AMP cells); compositions comprising expanded EE cell populations, and/or cell lysates and/or conditioned media derived therefrom, alone or in combination with each other and/or in combination with various extracellular matrices and/or devices and/or other suitable active agents.

Claims

1. A method for down-regulating an autoimmune response in a subject with an autoimmune disease, the method comprising the step of contacting the subject'"'"'s Peripheral Blood Mononuclear Cell (PBMC) population with a purified population of CD 117-negative Amnion-derived Multipotent Progenitor (AMP) cells such that the AMP cells inhibit the differentiation of monocytes in the PBMC population into mature dendritic cells, resulting in the down-regulation of the autoimmune response in the subject.

2. The method of claim 1 wherein the PBMC population which is contacted with CD 117-negative AMP cells are further contacted with one or more active agents.

3. The method of claim 2 wherein the one or more active agents is selected from the group consisting of a corticosteroid, a cyclosporine, a tacrolimus, a sirolimus, a methotrexate, an azathiopine, a mercatopurine, a cytotoxic antibiotic, a polyclonal antibody, a monoclonal antibody, an interferon, an opioid, a TNF binding protein, a mycophenolate, a FTY720, and another cell type.

4. The method of claim 3 wherein the monoclonal antibody is selected from the group consisting of an anti-T-cell receptor (CD23) and an anti-IL2 receptor (CD25) antibody.